AI Signal & Stock Analysis · Very Strong ↑
As of Aug 14 2026, 1:04 PM, AkshayaAI's signal for GMAB is Very Strong ↑; the stock is at $31.93 (+1.88% today); overbought (RSI 73); technical trend is Raise; news sentiment is positive.
Data as of Aug 14 2026, 1:04 PM. Informational analytics only — not investment advice.
| AI signal (Strength) | Very Strong ↑ |
|---|---|
| Price | $31.93 |
| Change today | +1.88% |
| RSI (14) | 73.25 |
| Relative volume | 1.59 |
| Composite (RMTPGV) score | 🔒 members |
| Market cap | $19.1B |
| Forward P/E | 18.79 |
| 52-week high | -9.9% away |
| 52-week low | +42.0% above |
| Technical trend | RAISE-2024-01-26 |
| News sentiment | Positive |
| Sector | Healthcare-Biotech |
| Next earnings | 8/6/2026 4:30:00 PM |
As of Aug 14 2026, 1:04 PM, AkshayaAI assigns GMAB (Genmab ADR) a Very Strong signal. The composite (RMTPGV) score and full factor breakdown are available to signed-in members.
GMAB's RSI is overbought (RSI 73). A reading above 70 is typically considered overbought and below 30 oversold.
GMAB is trading about 10% below its 52-week high and 42% above its 52-week low as of Aug 14 2026, 1:04 PM.
GMAB's next earnings date is 8/6/2026 4:30:00 PM.
GMAB is classified under Healthcare-Biotech in AkshayaAI's taxonomy.
AkshayaAI provides AI-generated, informational stock analytics for US and India markets. This is not personalized investment advice. Figures are as of Aug 14 2026, 1:04 PM and may not reflect real-time prices. Always do your own research.
Instant, data-backed answers — free to try.